Survivin and Programmed Death Ligand-1 as Possible Players in the Pathogenesis of Ulcerative Colitis: An Immunohistochemical Study

Reham Shehab El Nemr Esmail; Eman Hassan  Abdelbary

doi:10.3889/oamjms.2020.4868

Authors

Reham Shehab El Nemr Esmail Pathology Department, Faculty of Medicine, El-Fayoum University, Egypt
Eman Hassan Abdelbary Pathology Department, Faculty of Medicine, Zagazig University, Egypt

DOI:

https://doi.org/10.3889/oamjms.2020.4868

Keywords:

Survivin, Programmed death ligand-1, Ulcerative colitis

Abstract

BACKGROUND: Ulcerative colitis (UC) is a relapsing chronic inflammatory disorder, with many catastrophic complications. The pathogenesis of UC is not yet well understood. Exploring the exact immunologic pathogenesis of UC may eventually offer new therapeutic options.

AIM OF THE WORK: In this study, we proposed that survivin and programmed death ligand (PDL1) may have roles in the pathogenesis of UC.

MATERIALS AND METHODS: The study examined the immunohistochemical expression of both markers in the colonic epithelial cells and lamina propria in 43 cases of UC and 43 cases of non-specific chronic colitis (non-inflammatory bowel disease colitis).

RESULTS: The results uncovered that both survivin and PDL1 expression were significantly expressed in the colonic lamina propria cells in UC cases in comparison to colitis cases (p < 0.001). On the other hand, the expression of PDL1 was shown to be lost in the colonic mucosal cells in UC cases when compared to cases of the control group (p < 0.05).

CONCLUSION: The study, therefore, concluded that both survivin and PDL1 may play an important role in the UC pathogenesis and hence may be a novel interest in new therapeutic trends.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Akpinar MY, Ozin YO, Kaplan M, Ates I, Kalkan IH, Kilic ZM. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio predict mucosal disease severity in ulcerative colitis. J Med Biochem. 2018;37(2):155-62. https://doi.org/10.1515/ jomb-2017-0050 PMid:30581352

Bing X, Linlang L, Keyan C. Decreased Breg/Th17 ratio improved the prognosis of patients with ulcerative colitis. Can J Gastroenterol Hepatol. 2018;2018:5760849. https://doi. org/10.1155/2018/5760849 PMid:29765931

Feng W, Yong H, Fengshi D, John HK. Ulcerative colitis-associated long noncoding RNA, BC012900, regulates intestinal epithelial cell apoptosis. Inflamm Bowel Dis. 2016;22(4):782-95. https://doi.org/10.1097/mib.0000000000000691 PMid:26937624

Zhang S, Wang S, Miao C. Influence of microbiota on intestinal immune system in ulcerative colitis and its intervention. Front Immunol. 2017;8:1674. https://doi.org/10.3389/fimmu.2017.01674 PMid:29234327

Rajabian Z, Kalani F, Taghiloo S, Tehrani M, Rafiei A, Hosseini- Khah Z, et al. Over-expression of immunosuppressive molecules, PD-L1 and PD-L2, in ulcerative colitis patients. Iran J Immunol. 2019;16(1):62-70. PMid:30864556

Mikami T, Yoshida T, Akino F, Motoori T, Yajima M, Okayasu I. Apoptosis regulation differs between ulcerative colitis-associated and sporadic colonic tumors. Association with survivin and bcl-2. Am J Clin Pathol. 2003;119(5):723-30. https://doi.org/10.1309/ ylx4l4h36k54x92h PMid:12760292

Unruhe B, Schröder E, Wünsch D, Knauer SK. An old flame never dies: Survivin in cancer and cellular senescence. Gerontology. 2016;62(2):173-81. https://doi.org/10.1159/000432398 PMid:26159786

Gravina C, Wasén C, Garcia-Bonete MJ, Turkkila M, Erlandsson MC, Silfverswärd ST, et al. Survivin in autoimmune diseases. Autoimmun Rev. 2017;16(8):845-55. https://doi. org/10.1016/j.autrev.2017.05.016 PMid:28564620

Mezache L, Magro C, Hofmeister C, Pichiorri F, Sborov D, Nuovo G. Modulation of PD-L1 and CD8 activity in idiopathic and infectious chronic inflammatory conditions. Appl Immunohistochem Mol Morphol. 2017;25(2):100-9. https://doi. org/10.1097/pai.0000000000000298 PMid:27438510

Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer. 2013;49(9):2233-42. https:// doi.org/10.1016/j.ejca.2013.02.015 PMid:23478000

Ilie M, Hofman V, Dietel M, Soria J, Hofman P. Assessment of the PD-L1 status by immunohistochemistry: Challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016;468(5):511-25. https://doi.org/10.1007/ s00428-016-1910-4 PMid:26915032

Acosta-Gonzalez G, Ouseph M, Lombardo K, Lu S, Glickman J, Resnick MB. Immune environment in serrated lesions of the colon: Intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression. Hum Pathol. 2019;83:115-23. https://doi.org/10.1016/j.humpath.2018.08.020 PMid:30172913

Jakubowska K, Pryczynicz A, Piekarska VD, Famulski W, Ustymowicz KG. Immunohistochemical expression and serum level of survivin protein in colorectal cancer patients. Oncol Lett. 2016;12(5):3591-7. https://doi.org/10.3892/ol.2016.5075 PMid:27900041

Wyss J, Dislich B, Koelzer VH, Galván JA, Dawson H, Hädrich M, et al. Stromal PD-1/PD-L1 expression predicts outcome in colon cancer patients. Clin Colorectal Cancer. 2019;18(1):e20-38. https://doi.org/10.1016/j.clcc.2018.09.007 PMid:30389315

Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, et al. Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from western countries. Gastroentrol. 2018;155(4):1079-89. https://doi.org/10.1053/j.gastro.2018.09.014 PMid:29958857

Ebrahimiyan H, Aslani S, Rezaei N, Jamshidi A, Mahmoudi M. Survivin and autoimmunity; the ins and outs. Immunol Lett. 2018;193:14-24. https://doi.org/10.1016/j.imlet.2017.11.004 PMid:29155234

Rapti E, Gazouli M, Legaki E, Karamanolis G, Thomas D, Marinos E, et al. Association of survivin promoter polymorphisms with inflammatory bowel disease and response to antitumor necrosis factor therapy. Genet Test Mol Biomarkers. 2015;19(6):339-43. https://doi.org/10.1089/gtmb.2015.0036 PMid:25918954

Feng BS, Ma N, Zhang YY, Gao H, Zhang C, Li G, et al. Survivin impairs the apoptotic machinery in cd4+ t cells of patients with ulcerative colitis. J Innate Immun. 2020;12(3):226-34. https:// doi.org/10.1159/000500546 PMid:31330513

Pahlavan Y, Kahroba H, Samadi N, Karimi A, Ansarin K, Khabbazi A. Survivin modulatory role in autoimmune and autoinflammatory diseases. J Cell Physiol. 2019;234(11):19440-50. https://doi.org/10.1002/jcp.28725 PMid:31020660

Kerr KM, Hirsch FR. Programmed death ligand-1 immunohistochemistry: Friend or foe? Arch Pathol Lab Med. 2016;140(4):326-31. PMid:26756647

Liu C, GhayouriIan M, Brown S. Immunohistochemistry and special stains in gastrointestinal pathology practice. Diagn Histopathol. 2020;26(1):22-3.

Brusa D, Serra S, Coscia M, Rossi D, D’Arena G, Laurenti L, et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013;98:953-63. https://doi.org/10.3324/haematol.2012.077537 PMid:23300177

Tsuda S, Carreras J, Kikuti YY, Nakae H, Dekiden-Monma M, Tsuruya JI, et al. Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: Role of macrophages and regulatory markers in disease severity. Pathol Int. 2019;69:260-71. https://doi.org/10.1111/pin.12794

Beswick EJ, Grim C, Singh A, Aguirre JE, Tafoya M, Qiu S, et al. Expression of programmed death-ligand 1 by human colonic CD90+ stromal cells differs between ulcerative colitis and Crohn’s disease and determines their capacity to suppress Th1 cells. Front Immunol. 2018;9:1125. https://doi.org/10.3389/ fimmu.2018.01125 PMid:29910803

Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: The flip side of the wonder drugs. Virchows Arch. 2018;472(1):125-33. https://doi.org/10.1007/ s00428-017-2267-z PMid:29143108

Su Q, Zhang X, Shen X, Hou Y, Sun Z, Gao ZH. Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: Systems assessment. J Cancer. 2018;9(9):1614-22. https://doi.org/10.7150/jca.24200 PMid:29760800